Artivion Reports Third Quarter 2025 Financial Results

Core Insights - Artivion, Inc. reported strong financial performance in Q3 2025, achieving 16% constant currency revenue growth driven by significant increases in stent grafts and On-X products [2][4][12] - The company is raising its full-year 2025 revenue and adjusted EBITDA guidance, reflecting confidence in continued growth [5][6] Financial Performance - Total revenues for Q3 2025 were $113.4 million, an 18% increase on a GAAP basis and a 16% increase on a non-GAAP constant currency basis compared to Q3 2024 [4][12] - Net income for Q3 2025 was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $(2.3) million in Q3 2024 [4][12] - Adjusted EBITDA increased by 39% to $24.6 million in Q3 2025 compared to $17.7 million in Q3 2024 [12] Product Performance - Revenue growth was primarily driven by stent grafts, which grew by 38%, and On-X products, which grew by 25% year-over-year [2][12] - Preservation services and BioGlue also contributed to revenue growth, with increases of 5% and 2%, respectively [2] Strategic Initiatives - The company enrolled the first patient in the ARTIZEN trial for Arcevo, marking a significant milestone in its clinical programs [3] - Artivion presented new favorable clinical data from its AMDS PERSEVERE and PROTECT trials, further validating the benefits of its AMDS technology [3] Financial Outlook - Artivion raised its full-year 2025 revenue guidance to a range of $439 to $445 million, expecting constant currency growth of 13% to 14% [5] - The adjusted EBITDA guidance was also raised, now expecting growth between 24% and 28% for the full year 2025 [6]